Ellen Donnelly
Chief Executive Officer bei ABLIVA AB
Profil
Ellen K.
Donnelly is currently the Chief Executive Officer at Abliva AB since 2021.
She is also the Director at Modus Therapeutics AB since 2017.
Additionally, she holds the position of Independent Director at Modus Therapeutics Holding AB since 2020 and at AlzeCure Pharma AB since 2018.
Previously, she served as the Chief Executive Officer-Epigenetics Division at Juvenescence Ltd.
Dr. Donnelly holds a doctorate degree from Yale School of Medicine.
Aktive Positionen von Ellen Donnelly
| Unternehmen | Position | Beginn |
|---|---|---|
| ALZECURE PHARMA AB | Director/Board Member | 01.01.2018 |
| MODUS THERAPEUTICS HOLDING AB | Director/Board Member | 01.01.2020 |
| ABLIVA AB | Chief Executive Officer | 03.02.2021 |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Director/Board Member | - |
Ehemalige bekannte Positionen von Ellen Donnelly
| Unternehmen | Position | Ende |
|---|---|---|
Juvenescence Ltd.
 Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Corporate Officer/Principal | - |
Ausbildung von Ellen Donnelly
| Yale School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| ABLIVA AB | Health Technology |
| MODUS THERAPEUTICS HOLDING AB | Health Technology |
| ALZECURE PHARMA AB | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Finance |
